-
Request for comments on the statistical guidelines for clinical research of rare disease drugs
Time of Update: 2021-12-05
Clinical research of rare disease drugs often faces problems such as difficulty in enrollment, long enrollment time, limited sample size, high heterogeneity of enrolled subjects, and lack of effective treatment methods, which require higher quality of clinical research .
-
The 1.2 billion yuan market for adjuvant hypotension treatment drugs welcomes competitors!
Time of Update: 2021-12-05
Jinyao Pharmaceutical is the second domestic company that has been evaluated, which means that this 1 billion yuan market has ushered in competitors .
The second company that passed the consistency evaluation of norepinephrine bitartrate injection .
-
The 9th Biological Fermentation Exhibition in 2022, "March in Spring, Happy Gathering in Jinan" Fermentation Covenant is waiting for you
Time of Update: 2021-12-05
2022 The 9th Biological Fermentation Products and Technology Equipment Exhibition (Jinan) and Biological Industry Series Exhibition will be held in Shandong International Convention and Exhibition Center (No.
-
PARP inhibitor re-starts phase 0 clinical trials
Time of Update: 2021-12-05
AbbVie's PARP inhibitor Veliparib became the first drug to take a crab, and completed the first phase 0 clinical trial of a tumor drug.
-
A batch of pharmaceutical companies' 2021 annual performance forecasts have been released!
Time of Update: 2021-12-05
The four pharmaceutical companies that have anticipated net profit growth in 2021 include Yan'an Bikang, Hualan, and Zuoli Pharmaceuticals.
61%; in 2021, the net profit attributable to the owners of the parent company is expected to be approximately 197 million to 266 million yuan, an increase of approximately 141.
-
Eli Lilly initiates first head-to-head study of CGRP migraine drug
Time of Update: 2021-12-05
Last weekend, Eli Lilly announced the initiation of a phase 4 clinical trial to compare its monthly subcutaneous CGRP migraine drug Emgality with oral tablets Nurtec ODT for the preventive treatment of paroxysmal migraine (EM) .
-
500 million yuan of anti-gout drugs, two pharmaceutical companies have reviewed it in one day!
Time of Update: 2021-12-05
Prior to this, domestically produced febuxostat has been approved for listing, involving companies including Zhu Yangxin, Wanbang, and Hengrui.
The manufacturers involved include Jiangsu Wanbang (40mg, 16 tablets, winning price of 16.
-
The demand for high-end pharmaceutical equipment is growing stronger, and the market share is expected to continue to increase
Time of Update: 2021-12-05
From the above data, the market share of domestic high-end pharmaceutical equipment is continuing to increase, which also means that high-end equipment companies are ushering in opportunities and are expected to accelerate the pace of import substitution in the future .
-
Ten billion yuan in CTLA-4 antibody drug market, attracting local pharmaceutical companies to deploy
Time of Update: 2021-12-05
Hengrui Medicine announced on the evening of November 21 that it had reached a strategic cooperation and exclusive license agreement with CStone Pharmaceuticals on the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region .
-
The resignation of directors in the pharmaceutical industry, Zhendong Pharmaceutical also joins the ranks
Time of Update: 2021-12-05
Zhendong Pharmaceutical issued an announcement on the evening of November 19, stating that the company’s board of directors recently received a written application for resignation from director and president Ma Shifeng.
-
20 years of "marriage" finally broke up, Novartis sold 20.7 billion US dollars of Roche equity
Time of Update: 2021-12-04
Novartis will report the proceeds of the equity sale after the core adjustment, and the total proceeds are expected to be approximately US$14 billion .
-
Looking forward to 2022, which sub-tracks in the pharmaceutical and biological sector have great potential?
Time of Update: 2021-12-04
From the perspective of subdivisions, in the first three quarters of this year, the innovative drugs, medical devices, CXO and API sectors all showed rapid growth, while the revenue and net profit growth of the pharmaceutical retail sector declined slightly .
-
Recently, the resignation wave of pharmaceutical company executives is still fierce!
Time of Update: 2021-12-04
Kanghong Pharmaceutical issued an announcement stating that ChenSU applied to resign from the company's directorship due to personal reasons, and at the same time resigned from the position of vice president.
-
Analysis of Antihypertensive Drugs Used in Shanghai Sample Hospitals
Time of Update: 2021-12-04
Top ten antihypertensive drugs commonly used in Shanghai sample hospitalsData source: China Pharmaceutical Industry Information Center Hospital Prescription Analysis System (RAS)The top four drugs with the most dosage are L-Amlodipine, Amlodipine, Valsartan, and Metoprolol.
-
Another 32 proprietary Chinese medicines in Shanxi have been withdrawn from the Internet!
Time of Update: 2021-12-04
On November 23, Shanxi Province Pharmaceutical Equipment Centralized Bidding Purchasing Network issued the "Notice on Announcement of Some Enterprises' Application for Revocation of Online Procurement Eligibility for Platforms" (hereinafter referred to as the "Notice"), and 32 Chinese patent medicines including Qingreling Granules will be removed from the Internet , Involving 8 pharmaceutical companies .
-
Centralized procurement will reshape the pharmaceutical industry, and these three giants will accelerate their "run"
Time of Update: 2021-12-04
Therefore, with the deepening of centralized procurement in the future, pharmaceutical companies with strong innovation or transformation capabilities, such as pharmaceutical companies with high A stock market value, Hengrui Pharmaceuticals, Mindray Medical, and WuXi AppTec, may accelerate their transformation and growth .
-
Companies in the pharmaceutical industry continue to add and subtract, and actively embrace new changes in the market
Time of Update: 2021-12-04
For another example, on the evening of November 18, Kanghua Biological announced that the company reached a strategic cooperation and signed an agreement with Chengdu Xinran Bochuang Biotechnology Co.
-
Seeking future for domestic pharmaceutical equipment: technology and product manufacturing quality need to be improved
Time of Update: 2021-12-04
In recent years, it can also be seen that domestic pharmaceutical companies are starting to increase R&D investment and focus on personnel training, closely following the development trend of the biomedical industry and the application of new technologies, and continuously improve technological innovation capabilities and high-quality R&D.
-
The centralized procurement of medical consumables continues to deepen, and the procurement of low-value consumables is blooming everywhere
Time of Update: 2021-12-04
Low-value medical consumables and test reagents are included in the scope of centralized procurement .
It is worth noting that as provinces and cities have successively started to purchase low-value consumables, the prices of related products have also dropped significantly.
-
The seventh batch of nationally selected varieties meet the conditions (list attached)
Time of Update: 2021-12-04
In addition, "Minenet" has also sorted out a group of anti-tumor drugs that meet the requirements of the national centralized procurement to be reviewed .
According to data from Meinenet, the anti-tumor drug market is expected to reach 300 billion in 2025 .
